NFE2L2 and non-small cell lung carcinoma: With the development of evidence on the role of KEAP1/NFE2L2 pathway on chemotherapy resistance in pre-clinical NSCLC models (3), there have been increasing efforts to evaluate the impact of KEAP1/NFE2L2 mutations on the prognosis of survival in NSCLC patients.